Data for Seattle Genetics Inc.'s Adectris in the Phase III ALCANZA study secure the drug's bid – expected next year – for a new indication in CD30+ cutaneous T-cell lymphoma.
Pivotal ALCANZA Trial Secures Adcetris' Position in Cutaneous Lymphoma
Regarding FDA filing in new CTCL indication in 2017, Seattle Genetics is hoping for a label that covers all patients, regardless of positivity for CD30, though the Phase III ALCANZA study was done in biomarker expressers.
More from Anticancer
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
More from Therapy Areas
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.